文献速递临床生化临床免疫

丙戊酸诱导代谢功能障碍的临床与动物研究

Valproate acid (VPA)-induced dysmetabolic function in clinical and animal studies.
PubMed 文献 · Clin Chim Acta · 2017-02-02

该研究收集癫痫患者临床数据并在小鼠中开展临床前研究,发现使用丙戊酸的患者血糖、尿酸、甘油三酯及免疫细胞水平升高,而载脂蛋白A1和FABP4降低,且无药物性肝损伤;小鼠短期丙戊酸处理呈现代谢功能障碍趋势,附睾白脂肪组织FABP4呈剂量依赖性下调。结论提示丙戊酸可诱导FABP4受损的脂质代谢异常而不伴药物性肝损伤,FABP4可能作为敏感指标。

要点

  • 丙戊酸使用者血糖、尿酸、甘油三酯及白细胞、中性粒细胞升高。
  • 丙戊酸使用者循环载脂蛋白A1和FABP4降低,无药物性肝损伤。
  • 小鼠短期丙戊酸处理血清胰岛素、游离脂肪酸和甘油三酯升高,肝甘油三酯降低。

核心结论

  • 丙戊酸可诱导FABP4受损的脂质代谢异常而不伴药物性肝损伤。
  • FABP4可能作为丙戊酸诱导代谢功能障碍的敏感指标。

研究设计与样本

  • 收集癫痫患者临床数据,并在小鼠中开展临床前研究。

主要发现

  • 临床数据显示使用丙戊酸的患者血糖、尿酸、甘油三酯及免疫细胞(白细胞、中性粒细胞)水平高于临床诊断参照。
  • 使用丙戊酸的患者循环载脂蛋白A1和FABP4降低,无可见药物性肝损伤。
  • 小鼠短期丙戊酸处理呈现代谢功能障碍趋势,血清胰岛素、游离脂肪酸和甘油三酯升高,肝甘油三酯含量降低。
  • 免疫测定显示附睾白脂肪组织FABP4呈剂量依赖性下调。

临床怎么用

  • 监测丙戊酸使用者的血糖、尿酸、甘油三酯及免疫细胞水平。
  • 关注循环FABP4和载脂蛋白A1变化以评估代谢功能障碍。

局限性

  • 原文摘要未报告临床样本量、具体数值、P值及研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Valproate acid (VPA), a commonly used antiepileptic medicine, is found to be linked to developing dysmetabolic risk. However, the proposed mechanism remains completely unknown. METHODS: In this study, we collected data from patients with epilepsy and further investigated the preclinical study in mice. RESULTS: As results, the clinical data showed that VPA-used patients resulted in higher levels of blood glucose, urine acid, triglyceride (TG), and immune cells (leucocyte, neutrophil leucocyte) when compared to clinically diagnosed references, while circulating apolipoprotein A1 (Apob A1) and fatty acid binding protein 4 (FABP4) were reduced without visible drug-induced liver injury (DILI). In rodent study, short-term treatment of VPA to mice showed developing trend of metabolic dysfunction, as revealed in increased serum insulin and free fatty acid and TG, and decreased liver TG content. As shown in immunoassay, FABP4 of epididymal white adipose tissue (eWAT) was down-regulated dose-dependently. CONCLUSION: Collectively, our present findings indicate that VPA can induce FABP4-impaired lipid dysmetabolism without DILI. More notably, FABP4 may function as a sensitive indicator for VPA-induced metabolic dysfunction.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Li R, Liang L, Wu X, et al. Valproate acid (VPA)-induced dysmetabolic function in clinical and animal studies. Clin Chim Acta. 2017. PMID: 28161274. doi:10.1016/j.cca.2017.01.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。